GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (NAS:TGTX) » Definitions » Asset Turnover

TG Therapeutics (TG Therapeutics) Asset Turnover : 0.13 (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is TG Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. TG Therapeutics's Revenue for the three months ended in Dec. 2023 was $44.0 Mil. TG Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $330.3 Mil. Therefore, TG Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.13.

Asset Turnover is linked to ROE % through Du Pont Formula. TG Therapeutics's annualized ROE % for the quarter that ended in Dec. 2023 was -35.46%. It is also linked to ROA % through Du Pont Formula. TG Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -17.46%.


TG Therapeutics Asset Turnover Historical Data

The historical data trend for TG Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Asset Turnover Chart

TG Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.01 0.01 0.89

TG Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.04 0.08 0.60 0.13

Competitive Comparison of TG Therapeutics's Asset Turnover

For the Biotechnology subindustry, TG Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TG Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Asset Turnover falls into.



TG Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

TG Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=233.662/( (193.572+329.587)/ 2 )
=233.662/261.5795
=0.89

TG Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=43.971/( (331.067+329.587)/ 2 )
=43.971/330.327
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


TG Therapeutics  (NAS:TGTX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

TG Therapeutics's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-57.664/162.6355
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-57.664 / 175.884)*(175.884 / 330.327)*(330.327/ 162.6355)
=Net Margin %*Asset Turnover*Equity Multiplier
=-32.79 %*0.5325*2.0311
=ROA %*Equity Multiplier
=-17.46 %*2.0311
=-35.46 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

TG Therapeutics's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-57.664/330.327
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-57.664 / 175.884)*(175.884 / 330.327)
=Net Margin %*Asset Turnover
=-32.79 %*0.5325
=-17.46 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


TG Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


TG Therapeutics (TG Therapeutics) Business Description

Traded in Other Exchanges
Address
3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Executives
Laurence N Charney director MARVEL ENTERTAINMENT, INC., 417 FIFTH AVENUE, NEW YORK NY 10016
Sean A Power officer: CFO, Secretary and Treasurer 787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Michael S Weiss director, officer: CEO and President 750 LEXINGTON AVE, NEW YORK NY 10022
Sagar Lonial director C/O TG THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Yann Echelard director C/O LFB BIOTECHNOLOGIES, S.A.S., 3, AVENUE DES TROPIQUES LES ULIS, COURTABOEUF I0 91958
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kenneth Hoberman director 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Daniel Hume director 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
William James Kennedy director C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Lfb Biotechnologies S.a.s.u. 10 percent owner 3 AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91958
Mark Schoenebaum director 787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Opus Point Partners, Llc 10 percent owner 787 7TH AVENUE, 48TH FLOOR, NEW YORK NY 10019